KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adaptive Biotechnologies (ADPT) Common Equity: 2018-2025

Historic Common Equity for Adaptive Biotechnologies (ADPT) over the last 7 years, with Sep 2025 value amounting to $204.4 million.

  • Adaptive Biotechnologies' Common Equity fell 8.64% to $204.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $204.4 million, marking a year-over-year decrease of 8.64%. This contributed to the annual value of $202.7 million for FY2024, which is 34.27% down from last year.
  • As of Q3 2025, Adaptive Biotechnologies' Common Equity stood at $204.4 million, which was up 13.75% from $179.7 million recorded in Q2 2025.
  • Adaptive Biotechnologies' 5-year Common Equity high stood at $725.7 million for Q1 2021, and its period low was $179.7 million during Q2 2025.
  • Over the past 3 years, Adaptive Biotechnologies' median Common Equity value was $241.6 million (recorded in 2024), while the average stood at $273.4 million.
  • In the last 5 years, Adaptive Biotechnologies' Common Equity skyrocketed by 31.57% in 2021 and then crashed by 38.99% in 2024.
  • Quarterly analysis of 5 years shows Adaptive Biotechnologies' Common Equity stood at $604.1 million in 2021, then fell by 23.16% to $464.2 million in 2022, then plummeted by 33.56% to $308.4 million in 2023, then slumped by 34.27% to $202.7 million in 2024, then decreased by 8.64% to $204.4 million in 2025.
  • Its Common Equity stands at $204.4 million for Q3 2025, versus $179.7 million for Q2 2025 and $190.4 million for Q1 2025.